Baxter touts positive data from four-year haemodialysis study [Yahoo! Finance]
Outset Medical, Inc. (OM)
Company Research
Source: Yahoo! Finance
of dying after four years compared to those on traditional high-flux haemodialysis (HF HD). The 48-month observational cohort study showed that 1,092 dialysis patients using HDx therapy had about a 25% lower risk of dying from any cause over four years, compared to HF HD users. The study was conducted at 11 Baxter renal care services centres in Colombia. The expanded HDx therapy, used with Baxter's Theranova dialyser, employs an advanced medium cut-off (MCO) membrane which can filter out a broader range of molecules, including large-middle molecules which conventional HF HD struggles to remove. These molecules are linked to inflammation and cardiovascular disease, so efficient removal can lead to better patient outcomes. Baxter won de novo clearance from the US Food and Drug Administration (FDA) for the Theranova cartridge in 2020 and was launched outside of the US in 2016. Peter Rutherford, vice president of kidney care at Baxter, said: “It is very exciting to see the results
Show less
Read more
Impact Snapshot
Event Time:
OM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OM alerts
High impacting Outset Medical, Inc. news events
Weekly update
A roundup of the hottest topics
OM
News
- Outset Medical, Inc. (NASDAQ: OM) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock, up previously from $5.00.MarketBeat
- Outset Medical (OM) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Outset Medical to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire
- Novo weight loss therapy cuts mortality risk in kidney disease [Seeking Alpha]Seeking Alpha
- Analysts Are Updating Their Outset Medical, Inc. (NASDAQ:OM) Estimates After Its First-Quarter Results [Yahoo! Finance]Yahoo! Finance
OM
Earnings
- 5/8/24 - Beat
OM
Sec Filings
- 6/14/24 - Form 4
- 6/12/24 - Form 144
- 6/3/24 - Form 4
- OM's page on the SEC website